Takeda and Cardurion Pharmaceuticals have formed a new cardiovascular development partnership. Cardurion, a recently launched Boston-area based biotechnology company, is focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Cardurion is led by two physician scientists with extensive experience in cardiovascular science, medicine and drug development—Daniel Bloomfield, chief executive officer, and Michael Mendels...